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Abstract
Purpose—Patients with cancer experience acute and chronic symptoms caused by their 
underlying disease or by the treatment. While numerous studies have examined the impact of 
various treatments on symptoms experienced by cancer patients, there are inconsistencies 
regarding the symptoms measured and reported in treatment trials. This article presents a 
systematic review of the research literature of the prevalence and severity of symptoms in patients 
undergoing cancer treatment.
Methods—A systematic search for studies of persons receiving active cancer treatment was 
performed with the search terms of “multiple symptoms” and “cancer” for studies involving 
patients over the age of 18 years and published in English during the years 2001 to 2011. Search 
outputs were reviewed independently by seven authors, resulting in the synthesis of 21 studies 
meeting criteria for generation of an Evidence Table reporting symptom prevalence and severity 
ratings.
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Results—Data were extracted from 21 multi-national studies to develop a pooled sample of 4067 
cancer patients in whom the prevalence and severity of individual symptoms was reported. In 
total, the pooled sample across the 21 studies was comprised of 62% female, with a mean age of 
58 years (range: 18 to 97 years). A majority (62%) of these studies assessed symptoms in 
homogeneous samples with respect to tumor site (predominantly breast and lung cancer), while 
38% of the included studies utilized samples with mixed diagnoses and treatment regimens. 
Eighteen instruments and structured interviews were including those measuring single symptoms, 
multi-symptom inventories, and single symptom items drawn from HRQOL or health status 
measures. The MD Anderson Symptom Inventory (MDASI) was the most commonly used 
instrument in the studies analyzed (n=9 studies; 43%), while the Functional Assessment of Cancer 
Therapy (FACT-G), Hospital Anxiety and Depression Subscale (HADS-D), Medical Outcomes 
Survey Short Form-36 (SF-36), and Symptom Distress Scale (SDS) were each employed in two 
studies. Forty-seven symptoms were identified across the 21 studies which were then categorized 
into 17 logical groupings. Symptom prevalence and severity were calculated across the entire 
cohort and also based upon sample sizes in which the symptoms were measured providing the 
ability to rank symptoms.
Conclusions—Symptoms are prevalent and severe among patients with cancer. Therefore, any 
clinical study seeking to evaluate the impact of treatment on patients should consider including 
measurement of symptoms. This study demonstrates that a discrete set of symptoms is common 
across cancer types. This set may serve as the basis for defining a “core” set of symptoms to be 
recommended for elicitation across cancer clinical trials, particularly among patients with 
advanced disease.
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Introduction
Patients with cancer experience acute and chronic symptoms caused both by their 
underlying disease and by the often toxic treatments employed in oncology care.[1,2] 
Clinical investigators, regulators, and healthcare providers often focus on the prevention or 
cure of illness, whereas relief of symptoms is a paramount goal for patients. [3,4] Symptoms 
are a common reason healthcare is sought and an impetus for testing to definitively diagnose 
an illness or injury. Once treatment is implemented, symptomatic treatment toxicities 
frequently develop. [5]
While numerous studies have examined the impact of various treatments and medications on 
symptoms in patients receiving cancer treatment, a limitation in comparing these outcomes 
is the lack of a common or “core” set of patient-reported symptoms, consistently measured 
across studies. For example, one study may report an improvement in nausea with a 
specified treatment, another study may report worsening fatigue, leaving the clinician and 
patient comparing treatment efficacies and weighing side effects based upon disparate 
outcomes.
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These differences in symptom outcomes between studies to some extent can be attributed to 
the use of varying symptom assessment questionnaires and strategies. While there is value to 
focusing on specific symptoms in particular clinical contexts (e.g., pain in patients with 
metastatic prostate cancer to bone), there is also value in administration of a common set of 
symptoms both in order to characterize the broader impact of disease and treatment on the 
patient experience, and to enable cross-trial comparisons and aggregation of data. Therefore, 
in 2011, the National Cancer Institute sponsored a scientific meeting to identify a standard 
core set of patient-reported symptoms to be recommended across cancer clinical trials as 
well as existing questionnaires that are appropriate for assessing these symptoms. As a 
component of this initiative, a multidisciplinary team conducted a systematic review of the 
literature to identify studies that measure the prevalence and severity of symptoms in 
patients undergoing cancer treatment.
Search Methods
A systematic electronic search of PubMed was performed with the search terms of “multiple 
symptoms” and “cancer” (Figure 1). The search was limited to adults over the age of 18 
years, English language articles, and the years 2001 to 2011. Search outputs including the 
abstract were reviewed independently by seven authors, and full-text of papers deemed to be 
potentially relevant based on a priori criteria (i.e., containing evidence characterizing 
symptoms in patients being treated for cancer) for inclusion were examined. Hand searches 
of papers in reference lists were also performed. Studies were included if they evaluated 
multiple symptoms in persons receiving active cancer treatment regardless of cancer site, 
stage, treatment, or geographic location. The initial search retrieved 55 publications of 
which 19 were excluded as case studies,[6-8] studies of single symptoms,[9-12] symptoms 
at the end of life,[13,] presenting symptoms at the time of cancer diagnosis,[15,16] or were 
otherwise not research reports focused of multiple symptoms in persons with cancer.[17-24]
In 2009, Esther Kim et al[25] published a literature synthesis of cancer symptomotology in 
18 studies. This paper and four additional literature reviews[26-29] identified in our 
systematic search were excluded from this analysis. Instead, the findings by Esther Kim et 
al. (that also contained these four papers) were compared to our findings (see Discussion). 
Unlike the Esther Kim et. al. synthesis which only included studies that used the MD 
Anderson Symptom Inventory (MDASI), Memorial Symptom Assessment Scales (MSAS), 
or the Symptom Distress Scale (SDS), this present analysis intentionally did not limit to any 
specific assessment instrument so that a wide array of symptoms could be collated and 
analyzed across a broader range of studies.
Nine publications that failed to report symptom statistics[30-38] and one publication that 
was a secondary study of a sample already included in this analysis[39] were excluded, 
resulting in 21 studies included in this analysis.[40-60] Potentially relevant data were 
abstracted for the review including disease/treatment, sample, instrument used to measure 
symptoms, and symptom prevalence and severity. Where information about prevalence and 
severity was not presented, the authors were contacted by e-mail to obtain the necessary 
detail. Data were managed using Excel.
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Analysis and Synthesis Methodology
Table 1 provides a summary of the 21 studies that evaluated multiple symptoms in adult 
oncology patients receiving active treatment. Twelve of these studies used a cross-sectional 
design and 9 employed a longitudinal approach that included randomized clinical trials, a 
cross-over design, or structured interviews. The length of follow-up in the longitudinal 
studies ranged from 7 days to 18 months, with assessment time points typically concurrent 
with important milestones such as treatment cycles or return to the home community 
following allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
An aggregation of the demographics for the studies is presented in Table 2 and then 
prevalence and severity of symptoms by paper is presented in Table 3. To allow for 
comparisons between the cross-sectional and longitudinal studies, where possible, mean 
prevalence was computed by averaging the reported values across the available time points 
in the longitudinal studies. When this was not possible due to missing data, the baseline 
values were entered into the analysis as noted on this table.
A similar procedure was used for tabulating severity, although mean severity by symptom 
was often not reported. In addition, many of the studies only reported those symptoms in 
which the severity was classified as moderate to severe. Because there was variation in the 
range of the severity scales among the instruments used in the studies, mean values were 
linearly transformed to a 0-10 scale to facilitate comparisons. Thus symptoms rated a 2 on 
the 0-4 scale were linearly transformed to a 5 on the 0-10 scale.
Lastly, to assess if the most commonly used instruments asked about the most compelling 
symptoms to patients, thresholds by number of patients queried for the symptom were 
constructed. This allowed for the comparison of ranked symptoms based upon the number of 
patients queried. Thus symptoms that were assessed in 100 or more people were ranked by 
frequency and severity, symptoms assessed in 500 or more people, and then a final threshold 
of 1000 or more people. The lowest threshold of 100 people had the most symptoms ranked 
while creating the threshold of 1000 people limited the number of symptoms. Some 
symptoms found in this synthesis did not include query by at least 100 patients and were 
therefore not included in this rank ordering of symptoms by threshold level.
Characteristics of These Studies
Data were extracted from the reported studies to develop a pooled sample of 4067 cancer 
patients in whom the prevalence and severity of individual symptoms was reported. 
Individual studies contributed from 16 to 1433 participants; nine (43%) studies included a 
sample size less than 100. All of the investigations employed convenience samples. Eleven 
(52%) of the studies were conducted in the United States while the remainder were 
multinational as listed in the Table 2. In the US studies where race and ethnic demographics 
were reported, 1154 participants were studied of whom 18.5% of the samples were non-
white. Studies from other nations failed to distinguish race/ethnicity. In total, the pooled 
sample across the 21 studies was comprised of 38% male and 62% female, with a mean age 
of 58 years (range: 18 to 97 years).
Reilly et al. Page 4






















A majority (62%) of these studies assessed symptoms in homogeneous samples with respect 
to tumor site (predominantly breast and lung cancer), while 38% of the included studies 
utilized samples with mixed diagnoses and treatment regimens. Table 2 summarizes the 
characteristics of participants in the included studies by cancer disease site, stage, and 
treatment type. Persons with breast cancer were the single largest group by cancer site 
(approximately 25% of patients) followed by lung (approximately 20%). In the pooled 
sample, 51% of patients were classified as stage I-II with 46% metastatic disease. The 
largest majority of study participants were treated with chemotherapy, radiation, and/or 
surgery. Approximately 5% additionally of the participants additionally received 
Hematopoietic Stem Cell Transplantation (HSCT), with symptom assessment before and 
after this treatment. For these two longitudinal studies, the frequency and severity of 
symptoms was averaged across the various assessment times for this synthesis.
Symptom Assessment Instruments
Eighteen instruments listed in Figure 2 and structured interviews were used in the 21 studies 
included in this synthesis. Instruments included those measuring single symptoms, multi-
symptom inventories, and single symptom items drawn from HRQOL or health status 
measures. The MD Anderson Symptom Inventory (MDASI) was the most commonly used 
instrument in the studies analyzed (n=9 studies; 43%), while the Functional Assessment of 
Cancer Therapy (FACT-G), Hospital Anxiety and Depression Subscale (HADS-D), Medical 
Outcomes Survey Short Form-36 (SF-36), and Symptom Distress Scale (SDS) were each 
employed in two studies. The remaining instruments were represented just once.
Symptom Summary
Forty-seven symptoms were identified across the 21 studies which were then categorized 
into 17 logical groupings. While many studies only reported the most prevalent or severe 
symptoms, some reported every symptom acknowledged by patients. In an attempt to be as 
inclusive as possible, all symptoms reported were included in this synthesis.
A summary of the prevalence and mean severity rates (when available) for these various 
symptoms are provided in Table 4. This table is organized in descending order according to 
the prevalence of the measurement of symptom groupings as highlighted in blue. Thus, all 
of the studies in this synthesis measured and reported frequency and/or severity of the 
symptoms of fatigue and pain, 91% of the studies similarly reported symptoms of sleep 
issues, while only 4.5% reported on symptoms of hair loss or other appearance issues.
The pooled prevalence and mean severities reported in Table 4 were calculated by 
aggregating all queries for that specific symptom across studies to provide a pooled 
prevalence per symptom. Where possible, symptoms of the same nature but labeled 
differently such as anorexia and decreased appetite were combined into one symptom. This 
was possible when only one term was used in a study providing one statistic; however, some 
symptom terms which could be synonymous for each other were often reported as separate 
items in the same study. Examples include the terms “fatigue”, “lack of energy”, and 
“weakness”. Each is listed separately in this synthesis to assure the capture of constructs that 
may be related but distinct. Of note, while all of studies measured and thus reported the 
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symptom of fatigue, 59.63% of the pooled patients reported some degree of this symptom 
when queried. Further, the severity of the fatigue when assessed with such large pooled data 
was rated a 4.62 on a 0-10 scale.
Symptom Prevalence
Given the large spread of sample sizes, the variety of instruments utilized and the 
identification of 47 separate symptoms presented in Table 3, it was determined that the most 
appropriate method to rank symptoms in a systematic, unbiased, and interpretable fashion 
was to compare the symptom prevalence by aggregated sample size thresholds. Three 
thresholds were constructed for combined samples of greater than 100 patients, greater than 
500 patients and greater than 1000 patients who were queried for the symptom. Thus the 
most inclusive threshold was 100 taking into account all symptoms in which at least 100 
patients across studies were queried. Not included in this analysis then were symptoms such 
as irritability which was only assessed in a total of 85 patients in 2 studies or headache 
included in only one study of 31 patients.
As depicted in Table 5 depending upon the threshold level selected, the rank order of the 
prevalence changed. For a threshold of 100 patients, Nocturia was the most frequently 
reported symptom followed by Fatigue and Cough. When the threshold was raised to a 
minimum of 500 patients assessed for the symptom, Cough was replaced by Insomnia/
Disturbed Sleep. Finally, when raised to a sample threshold of 1000 patients, Fatigue, 
Insomnia/Disturbed Sleep, and Pain are the top three most reported symptoms. Thus as will 
be discussed later, while nocturia was the most prevalent symptom with 74.8% of patients 
reporting, it was only queried in 507 patients in 2 studies.[45,49]
Symptom Severity
A similar approach was taken in evaluating the symptom severity, and is presented in Table 
6. In studies with a sample threshold of 100 patients, Worry had the highest mean severity 
followed by Sexual Dysfunction and Edema. By comparison, when the higher threshold of 
500 patients was selected, most of the symptoms in the lower threshold of 100 patients were 
removed and by the 1000 patient threshold, all but one symptom was replaced with the top 
three being Fatigue, Insomnia/Disturbed Sleep, and Anorexia/Appetite changes. As with the 
symptom prevalence, fewer studies assessed worry (three studies)[41,46,51] and sexual 
dysfunction (two studies)[45,51] resulting in a smaller patient pool, yet the compelling 
severity reported may indicate the need for further assessment as a routine symptom 
measure.
Discussion
Forty-seven distinct symptoms were reported in the 21 studies of this literature synthesis 
across different cancers. Most studies employed instruments that assessed for symptoms of 
Fatigue & Weakness (100% of studies), Pain (100% of studies), Sleep Issues (91% of 
studies), Anorexia & Weight loss (91% of studies), GI Issues such as nausea and vomiting 
(81% of studies), Affect issues such as depression and irritability (76% of studies), and 
Respiratory Issues such as cough and dyspnea (76% of studies). Fewer studies assessed 
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symptoms related to Urinary Elimination Issues (19% of studies), Skin and Wound Issues 
(19% of studies), Hot Flashes/sweating (14% of studies), Sexual Dysfunction (10% of 
studies), Fever (14% of studies), and Hair Loss/Appearance (5% of studies), yet the 
prevalence and severity of some of these symptoms was greater than the more commonly 
assessed symptoms.
This disparity is most obvious when evaluating the prevalence and severity by threshold 
levels. Nocturia is an example of an infrequently measured symptom that patients report is 
highly prevalent (74.8%) and moderately severe (4.07 on scaled of 0-10). Further analysis of 
the two studies that assessed for nocturia reveals that one study was completed in the US 
and the other in Turkey, that adequate sample sizes of 220 and 287 were included, and that 
various cancer sites were involved with lung being the predominant cancer.[45,49] Given 
the heterogeneous nature of the studies, this finding suggests that nocturia is a symptom that 
has been infrequently assessed, but which necessitates further systematic evaluation and 
consideration as a symptom to assess in a broad range of cancers. Similar arguments can be 
made for sexual dysfunction[45,51] and cough[45,46,48,51,53] which each were reported by 
patients in disparate studies (nation, cancer site, sample sizes) as highly prevalent and of 
moderate to high severity.
Findings from this literature synthesis are most useful when compared with the research 
synthesis by Esther Kim et. al.[25] Many similarities between the two syntheses exist 
including the similar mean age of 58 and 59 years, a predominance of heterogeneous cancer 
diagnoses (62% and 50%), and when reported for US studies, an approximate 18% non-
Caucasian sample. Differences include a greater range of sample sizes in this present 
analysis (16- 1433 compared to 26-527) and a greater proportion of females in this analysis 
(62% vs. 48%). Whereas Esther Kim et. al. limited their review to only studies that 
employed the MDASI, MSAS, or the SDS, this present analysis included studies employing 
any symptom assessment tools.
Table 7 presents a comparison of the most prevalent symptoms in this synthesis to the top 10 
identified by Esther Kim et. al. These are presented in descending prevalence for this current 
synthesis. All but three of the symptoms (nocturia, outlook, and weakness) included in this 
synthesis were also included in the Esther Kim et. al. synthesis. Unfortunately, the synthesis 
by Esther Kim et. al. only published the aggregation of the top 10 symptoms. As presented 
in this table, while the vast majority of symptoms were assessed (as indicated by the 
instrument used), comparisons cannot be drawn because the pooled prevalence numbers for 
all but the top 10 symptoms were not published. In comparing our findings to those of 
Esther Kim et.al., similarities in the prevalence of fatigue, insomnia, dry mouth, tiredness, 
feeling nervous, distress, and depression were noted, however differences are observed 
between the rates of irritability, pain, and worry are evident. Further, highly prevalent 
symptoms such as nocturia, lack of energy, outlook, cough, anorexia, dyspnea, and difficulty 
concentrating did not make Esther Kim et. al.'s list of the most prevalent symptoms. The 
Kim study did not aggregate severity data.
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Limitations and Future Directions
As with any literature synthesis, findings must be tempered by acknowledging publication 
bias as only published manuscripts were included in this literature synthesis. Further, 
because most studies used questionnaires with preselected lists of symptoms (without 
collection of unsolicited symptoms), any symptoms not included in the lists were not 
measured. Therefore, systematic under-reporting of symptoms which could be prevalent and 
severe in a population is possible in the included studies. An example of this is nocturia, 
which when elicited was prevalent and severe, but was infrequently systematically elicited 
in studies. Future studies should included a two-step methodology, starting with qualitative 
work in which patients in a given population are interviewed in groups or individually to 
determine likely prevalent and severe symptoms, followed by questionnaire administration 
in a larger sample. Over-representation of studies in breast, colorectal and lung cancer may 
have yielded a disproportionate influence on the results, and work parallel to this paper 
supported by the NCI is evaluating prevalence and severity of symptoms by cancer type and 
stage.
It is unclear if symptoms reported in this analysis are attributable to the morbidity of cancer, 
to side effects of treatment, to accumulated toxicities of prior treatment, or to comorbidities. 
As previously noted, this is a synthesis of cross-sectional studies and longitudinal studies 
whereby symptoms in the longitudinal studies were average across the measurement times, 
and no control was made for cross-sectional sampling related to the time of symptom 
measurement (i.e.: at diagnosis, following treatment, or at another arbitrary point in time). In 
addition, attribution is beyond the scope of this paper, but is a salient consideration because 
the impetus for measuring symptoms in a given clinical trial may be contingent on the cause 
of the symptom. For example, a trial seeking to evaluate whether a cancer-related symptom 
improves with active treatment may yield a negative result if the principal driver of 
measured symptoms is toxicity or comorbidity. Therefore, any given clinical trial aiming to 
measure symptoms should provide a rationale specific to the population and interventions 
regarding why particular symptoms were selected, and their suspected cause and 
hypothesized direction of change.
This synthesis is focused on the prevalence and severity of symptoms and did not assess 
measures of health-related quality of life domains such as enjoyment of life or physical 
functioning. Future work will evaluate these areas.
Conclusion
Symptoms are prevalent and severe among patients with cancer. Therefore, any clinical 
study seeking to evaluate the impact of treatment on patients should consider including 
measurement of symptoms. Without such an assessment, the picture of the patient 
experience is incomplete.[61] Symptoms may be due to various etiologies, and 
understanding their trajectories in a given context is essential to profiling both the benefits 
and harms of treatment. This study demonstrates that a discrete set of symptoms is common 
across cancer types. This set may serve as the basis for defining a “core” set of symptoms to 
be recommended for elicitation across cancer clinical trials, particularly among patients with 
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advanced disease. Indeed, the NCI is currently engaged in such an activity, which serves as 
the impetus for this review. It is notable that a number of existing multi-symptom 
questionnaires already include a set of pre-specified of symptoms. It is the authors' hope that 
the data included in this review will assist in the design of future studies and questionnaires, 
and in improved methods for assessing the prevalence and severity of symptoms in cancer 
populations.
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Figure 2. Instrument List
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Table 3
Prevalence and severity of symptoms by paper
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Table 4
Summary of pooled prevalence and pooled mean severity rates (when available)
Number of Patients 
Reporting Symptom
Total sample of 
Patients Queried Pooled Prevalence (%) Mean Severity
Fatigue & Weakness (100% of studies)
Generalized Fatigue 2177 3651 59.63 4.62
Tiredness/Drowsiness 999 2310 43.25 3.37
Lack Of Energy 36 54 66.67
Weakness 222 636 34.91 5.00
Pain (100% of studies)
Generalized/unspecified pain 1880 3914 48.03 3.44
Headache 7 31 22.58
Abdominal Pain 5.44
Sleep Issues (91% of studies)
Insomnia/Disturbed Sleep 1792 3675 48.76 4.15
Anorexia & Weight loss (91% of studies)
Weight Loss 129 321 40.19 5.94
Anorexia/Appetite changes 1539 3388 45.43 3.89
GI Issues (81% of studies)
Bloating 9 54 16.67 0.98
Bowel Changes 108 260 41.54 2.13
Constipation 117 349 33.52 2.25
Feeling Sick 18 100 18.00 2.20
N&V 61 236 25.85 1.20
Nausea 670 1672 40.07 2.50
Vomiting 392 1459 26.87 2.09
Diarrhea 52 349 14.90 1.15
Affect (76% of studies)
Depression/Sadness 983 2856 34.42 2.70
Irritability 44 85 51.76
Worry 58 161 36.02 7.75
Feeling Nervous 23 54 42.59
Distress 887 2149 41.28 2.36
Outlook 35 57 61.40 2.00
Respiratory Issues (76% of studies)
Cough 208 401 51.87 5.13
Wheezing 5 16 31.25
Difficulty breathing/Dyspnea 681 1560 43.65 2.78
Impaired Cognition (67% of studies)
Difficulty Concentrating/Remembering 693 1590 43.58 3.05
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Number of Patients 
Reporting Symptom
Total sample of 
Patients Queried Pooled Prevalence (%) Mean Severity
Oral & Swallowing Issues (62% of studies)
Altered Taste 87 274 31.75 3.50
Dry Mouth 1248 2610 47.82 3.49
Oral Lesions 12 234 5.13 0.45
Dysphagia 69 274 25.18 3.13
Neurologic Issues (57% of studies)
Poor Coordination 55 300 18.33 5.37
Mobility 29 285 10.18
Dizziness 80 305 26.23 4.68
Numbness/Tingling 364 875 41.60 2.21
Unspecified Neurologic 4 184 2.17
Edema (29% of studies)
Edema 102 711 14.35 6.57
Urinary Elimination Issues (19% of studies)
Urinary problems 14 85 16.47 4.25
Nocturia 379 507 74.75 4.07
Skin and Wound Issues (19% of studies)
Skin changes 7 54 12.96
Wound/Pressure Sore 21 121 17.36
Itching 13 134 9.70 4.15
Hot Flashes/sweating (14% of studies)
Hot Flashes/sweating 156 556 28.06 6.47
Fever (14% of studies)
Fever 19 111 17.12 2.81
Sexual Dysfunction (10% of studies)
Sexual Dysfunction 101 274 36.86 6.90
Hair Loss/Appearance (5% of studies)
Hair Loss/Appearance 34 161 21.12
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Table 7
Comparison of Prevalence statistics between this literature synthesis and Esther Kim et. al.
Pooled Prevalence Mean Severity Esther Kim et. al. Prevalence
Nocturia 74.75 4.07 *
Lack Of Energy 66.67 MSAS
Outlook 61.4 2 *
Generalized Fatigue 59.63 4.62 62%
Cough 51.87 5.13 MSAS
Irritability 51.76 37%
Insomnia/Disturbed Sleep 48.76 4.15 41%
Generalized/unspecified pain 48.03 3.44 36%
Dry Mouth 47.82 3.49 42%
Anorexia/Appetite changes 45.43 3.89 MDASI, MSAS, SDS
Difficulty breathing/Dyspnea 43.65 2.78 MDASI, MSAS, SDS
Difficulty Concentrating/Remembering 43.58 3.05 MDASI, MSAS, SDS
Tiredness/Drowsiness 43.25 3.37 36%
Feeling Nervous 42.59 45%
Numbness/Tingling 41.6 2.21 MDASI & MSAS
Bowel Changes 41.54 2.13 MSAS & SDS
Distress 41.28 2.36 34%
Weight Loss 40.19 5.94 MSAS
Nausea 40.07 2.5 MDASI, MSAS, SDS
Sexual Dysfunction 36.86 6.9 MSAS
Worry 36.02 7.75 54%
Weakness 34.91 5 *
Depression/Sadness 34.42 2.7 39%
Key for symptom assessment in the Esther Kim et. al. synthesis: MDASI= MD Anderson Symptom Inventory, MSAS= Memorial Symptom 
Assessment Scales, SDS= Symptom Distress Scale,
*
=not assessed
Support Care Cancer. Author manuscript; available in PMC 2015 January 20.
